Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Study	Sample (M/F)	Age, mean	Country	Last visit (mo)	Intervention	Helicobacter pylori eradication
Ang, 2006	130 (47/83)	38.0	Singapore	12	LAC	73.2%
Blum, 1998	328 (136/192)	47.0	Global	12	OAC	79%
Chiba, 2002	394 (148/246)	49.5	Canada	12	OMC	75%
Dhali, 1999	62 (44/18)	32.5	India	12	BMTe	87.5%
Froehlich, 2001	144 (64/80)	44.6	Switzerland	12	LAC	75%
Gisbert, 2004	50 (15/35)	41.5	Spain	12	OAC	76%
Greenberg, 1999	100 (31/69)	46.5	United States	12	OC	70.5%
Gwee, 2009	82 (38/44)	40.4	Singapore	12	OCT	68.3%
Hsu, 2001	161 (78/83)	50.9	China	12	LMTe	78%
Koelz, 2003	181 (74/107)	47.5	Switzerland	6	AO	51.7%
Koskenpato, 2001	151 (52/99)	51.7	Finland	12	AMO	82%
Lan, 2011	195 (89/106)	47.4	China	3	RAC	85.7%
Malfertheiner, 2003	800 (380/420)	46.2	Germany	12	LAC	63.9%
Mazzoleni, 2006	89 (20/69)	41.3	Brazil	12	LAC	91.3%
Mazzoleni, 2011	404 (86/318)	46.0	Brazil	12	OAC	88.6%
McColl, 1998	318 (155/163)	42.1	United Kingdom	12	AMO	88%
Miwa, 2000	85 (40/45)	51.5	Japan	3	OAC	85.4%
Naeeni, 2002	157 (47/110)	32.5	Iran	9	ABM	52.6%
Sodhi, 2013	519 (169/350)	44.5	India	12	OAC	69.9%
Talley, 1999	293 (133/160)	46.4	United States	12	LCA	80%
Talley, 1999 (ORCHID)	275 (98/177)	50.0	Australia	12	OAC	85%
Varannes, 2001	253 (112/141)	51.0	France	12	RaAC	69%
Varasa, 2008	48 (21/27)	37.0	Spain	12	RA	81.4%
Xu, 2013	396 (135/261)	40.0	China	12	ACE	76.36%
Zanten, 2003	157 (72/81)	48.0	Canada	12	LCA	82%

M/F: Male/female; A: Amoxillin; B: Bismuth salt; C: Clarithromycin; E: Esoprazole; F: Furazolidone; L: Lansoprazole; M: Metronidizole; O: Omeprazole; R: Rabeprazole; Ra: Ranitidine; T: Tinidazole; Te: Tetracycline.